Gradientech distributor starts multicenter study at four hospitals in Italy
The diagnostics company Gradientech today announces that a.d.a. SRL, its exclusive distributor for the Italian market, is starting a multicenter study in the Lombardia region of Italy for the QuickMIC® system, designed for ultra-rapid antibiotic susceptibility testing (AST) directly from blood culture.
The multicenter study, to be performed at four hospitals in the Lombardia region in the Milan area, is performed in collaboration with the Italian Society for Clinical Microbiology (AMCLI) and aims at developing new recommendations for rapid AST for Italian healthcare. The study will investigate the performance necessary for rapid AST systems to enable more efficient treatment of patients with resistant blood infections, considering laboratory opening hours, typical sample flows and different patient subpopulations. “The goal of the study is to inform the first rapid AST policy and recommendations for best practices by AMCLI,” says Dr. Pierangelo Clerici, AMCLI President.
“Rapid AST technology is becoming increasingly prevalent in Italy to address the widespread emergence of antibiotic resistance within the Italian healthcare system. QuickMIC delivers precise and accurate AST-results in just 2-4 hours, which is essential to confirm and adjust antimicrobial treatment in a timely manner for best practice,” says Andrea Grillo, Managing Director and Pietro Lombardi, Scientific Director of a.d.a. SRL, Gradientech’s exclusive distributor in Italy.
The ultra-rapid and precise antibiotic susceptibility testing results of QuickMIC® contribute to timely and effective management of sepsis patients, helping clinicians make faster antibiotic treatment decisions. Its modular design offers affordable scaling possibilities, making QuickMIC suitable for both small and large hospital laboratories. QuickMIC and its gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, contributes to the effective management of sepsis patients by supporting antibiotic treatment decisions in record time. This helps save lives, reduce healthcare costs, and combat the spread of antibiotic resistance – one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.